	US 12,378,302 B2
	Fusion molecules and uses thereof
Doron Lipson, Chestnut Hill, MA (US); Roman Yelensky, Newton, MA (US); Joel Robert Greenbowe, Cambridge, MA (US); and Jie He, Newton, MA (US)
Assigned to Foundation Medicine, Inc., Boston, MA (US)
Filed by Foundation Medicine, Inc., Cambridge, MA (US)
Filed on Nov. 30, 2021, as Appl. No. 17/539,023.
Application 17/539,023 is a division of application No. 14/440,569, granted, now 11,230,589, previously published as PCT/US2013/068604, filed on Nov. 5, 2013.
Claims priority of provisional application 61/763,442, filed on Feb. 11, 2013.
Claims priority of provisional application 61/722,533, filed on Nov. 5, 2012.
Prior Publication US 2022/0169703 A1, Jun. 2, 2022
Int. Cl. C12N 15/62 (2006.01); C07K 14/47 (2006.01); C07K 14/71 (2006.01); C07K 16/18 (2006.01); C07K 16/28 (2006.01); C07K 16/40 (2006.01); C12N 9/96 (2006.01)

CPC C07K 14/71 (2013.01) [C07K 14/47 (2013.01); C07K 16/18 (2013.01); C07K 16/2863 (2013.01); C07K 16/40 (2013.01); C12N 9/96 (2013.01); C12N 15/62 (2013.01)]

10 Claims

1. A method of treating a subject having cancer, comprising:

acquiring knowledge of the presence, in the subject, of an LMNA-NTRK1 fusion polypeptide, or a nucleic acid molecule encoding the LMNA-NTRK1 fusion polypeptide, wherein:

(i) the LMNA-NTRK1 fusion polypeptide comprises encoded exons 1-5 of SEQ ID NO: 20 and encoded exons 12-17 of SEQ ID NO:22, and a fusion junction comprising encoded exon 5 of SEQ ID NO:20 directly fused to encoded exon 12 of SEQ ID NO:22, or

(ii) the nucleic acid molecule encoding the LMNA-NTRK1 fusion polypeptide comprises exons 1-5 of SEQ ID NO:19 and exons 12-17 of SEQ ID NO:21, and a fusion junction comprising exon 5 of SEQ ID NO:19 directly fused to exon 12 of SEQ ID NO:21; and

administering to the subject an effective amount of a kinase inhibitor,

wherein the cancer is non-Langerhans histiocytosis.